DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Gender Disparity and Hormones in Cystic Fibrosis

Information source: University of Texas Southwestern Medical Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cystic Fibrosis (CF)

Intervention: Loestrin (norethindrone acetate and ethinyl estradiol) (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University of Texas Southwestern Medical Center

Official(s) and/or principal investigator(s):
Raksha Jain, MD, MSCI, Principal Investigator, Affiliation: UT Southwestern Medical Center

Overall contact:
Ashley Keller, MPH, Phone: 214-648-2817, Email: ashley.keller@utsouthwestern.edu

Summary

The objective of this study is to investigate the impact of hormones on lung disease in Cystic Fibrosis (CF) patients. Due to improved therapies, CF patients are living longer and healthier lives than they did 20 years ago. However, females have been shown to have a survival disadvantage. The median life expectancy is 33 in women and 37 in men with CF. The hypothesis is that estrogen and/or progesterone negatively impact lung health in CF. Therefore, understanding the impact of sex hormones (including the use of birth control pills) on the disease process is increasingly important. The purpose of this study is to determine if lung function, respiratory symptoms, or various markers of lung health change during different phases of the natural ovulatory cycle in order to understand if estrogen or progesterone hormones are impacting the disease relative to fluctuations in men with stable testosterone levels. The research objectives of this project are to:

- Determine if lung function, respiratory symptoms, or various markers of lung health

change during different hormonal phases of the ovulatory cycle in women.

- Determine if men change lung function, respiratory symptoms, or various markers of lung

health over time.

- Determine if oral contraceptive pills in women stabilize fluctuations in symptoms and

improve lung health.

Clinical Details

Official title: Gender Disparity and Hormones in Cystic Fibrosis

Study design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Change in percent predicted forced expiratory volume in 1 second (FEV1)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male and female cystic fibrosis patients

- Must be greater than or equal to 18 years of age.

- All subjects must understand and sign the informed consent.

- Subjects must have the ability to read and write in English.

- Female subjects starting this study must be willing to use a double barrier method of

birth control (such as condom or diaphragm) used with a spermicide (a substance that kills sperm), while participating in the study. Exclusion Criteria for Main Study:

- Women who are pregnant, breast feeding, or who have had an oophorectomy.

- Women who have received a hormone contraceptive injection (such as Depo Provera)

within the last 3 months. Exclusion Criteria for Substudy:

- Men

- Women who have a history of breast cancer, abnormal vaginal bleeding, liver disease,

coronary artery disease, cerebrovascular disease, uncontrolled hypertension, diabetes mellitus with vascular disease, or have had a stroke, heart attack, or blood clot within the past year, due to a possible reaction to Loestrin.

- Women who currently smoke cigarettes, due to the increased risk of serious

cardiovascular events with Loestrin use.

Locations and Contacts

Ashley Keller, MPH, Phone: 214-648-2817, Email: ashley.keller@utsouthwestern.edu

Children's Medical Center, Dallas, Texas 75207, United States; Recruiting
Ashley Keller, MPH, Phone: 214-648-2817, Email: ashley.keller@utsouthwestern.edu
Raksha Jain, MD, MSCI, Principal Investigator

UT Southwestern Medical Center, Dallas, Texas 75390, United States; Recruiting
Ashley Keller, MPH, Phone: 214-648-2817, Email: ashley.keller@utsouthwestern.edu
Raksha Jain, MD, MSCI, Principal Investigator
David Finklea, MD, Sub-Investigator

Additional Information

Starting date: December 2013
Last updated: January 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017